IP Library Granted Patent US 8,414,912
Granted Patent B2
US 8,414,912 · App. 12/636,671 · Granted Apr 9, 2013

Contact lens drug delivery device

Inventors: Joseph B. Ciolino (Boston, MA); Todd R. Hoare (Cambridge, MA); Daniel S. Kohane (Newton, MA)
Assignees: Massachusetts Institute of Technology; Children's Medical Center Corporation; Massachusetts Eye and Ear Infirmary
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,414,912
App. No.
12/636,671
Granted
Apr 9, 2013
Kind
B2
Abstract

The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner.

Claims (38)

1. A drug-eluting contact lens comprising:

an optical pathway wherein a line of vision of a wearer of the contact lens passes through the optical pathway; and

a continuous drug carrying zone comprising at least one drug for release by the contact lens proximate an eye of the wearer, the zone surrounding the optical pathway but not residing in the optical pathway, wherein the drug carrying zone is encapsulated by a lens material.

2. A drug-eluting contact lens as in claim 1 , wherein the drug carrying zone comprises a drug release material.

3. A drug-eluting contact lens as in claim 2 , wherein the drug release material comprises a non-polymeric excipient.

4. A drug-eluting contact lens as in claim 2 , wherein the drug release material comprises a multi-layered structure.

5. A drug-eluting contact lens as in claim 2 , wherein the contact lens is dimensioned so that, when worn by a subject, the drug release material is positioned over the conjunctiva.

6. A drug-eluting contact lens as in claim 1 , wherein the contact lens contains at least 1 mg of the at least one drug.

7. A drug-eluting contact lens as in claim 1 , wherein the contact lens contains at least 100 mg of the at least one drug.

8. A drug-eluting contact lens as in claim 1 , wherein the at least one drug comprises a first drug and a second drug, wherein the first drug is released at a different rate than the second drug.

9. A drug-eluting contact lens as in claim 1 , wherein the at least one drug comprises an anti-infective agent, an anesthetic agent, an anti-VEGF agent, an anti-inflammatory agent, a biological agent, a keratitis treatment composition, and/or an intraocular pressure reducing agent.

10. A drug-eluting contact lens as in claim 1 , wherein the at least one drug is released over a period of at least 720 hours.

11. A drug-eluting contact lens as in claim 1 , wherein the at least one drug is released at a rate of at least 1 microgram per hour.

12. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 120 hours.

13. A drug-eluting contact lens as in claim 1 , wherein the at least one drug is released at a rate of at least 0.005 micrograms per hour.

14. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 168 hours.

15. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 720 hours.

16. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 2160 hours.

17. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 2880 hours.

18. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 4800 hours.

19. A drug-eluting contact lens as in claim 1 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 9600 hours.

20. A drug-eluting contact lens as in claim 2 , wherein the drug release material comprises a polymer.

21. A drug-eluting contact lens comprising:

a hydrogel lens material encapsulating a drug-containing polymer film containing at least one drug,

wherein the contact lens provides substantially zero-order release of the at least one drug for at least 168 hours.

22. A drug-eluting contact lens as in claim 21 , wherein the contact lens is structured and dimensioned so that, when worn by a subject, the hydrogel lens material crossing an optical axis of the subject is optically transparent.

23. A drug-eluting contact lens as in claim 21 , wherein the contact lens contains at least 1 mg of the at least one drug.

24. A drug-eluting contact lens as in claim 21 , wherein the contact lens contains at least 10 mg of the at least one drug.

25. A drug-eluting contact lens as in claim 21 , wherein the contact lens provides substantially zero-order release of the at least one drug over a period of at least 720 hours.

26. A drug-eluting contact lens as in claim 21 , wherein the at least one drug is released at a rate of at least 0.1 micrograms per hour.

27. A drug-eluting contact lens comprising:

a hydrogel lens material encapsulating a drug-containing polymer film containing at least one drug,

wherein the contact lens provides release of the at least one drug at therapeutically effective amounts for at least 168 hours.

28. A drug-eluting contact lens as in claim 27 , wherein the contact lens is structured and dimensioned so that, when worn by a subject, the hydrogel lens material crossing an optical axis of the subject is optically transparent.

29. A drug-eluting contact lens as in claim 27 , wherein the contact lens contains at least 1 mg of the at least one drug.

30. A drug-eluting contact lens as in claim 27 , wherein the contact lens contains at least 10 mg of the at least one drug.

31. A drug-eluting contact lens as in claim 27 , wherein the contact lens provides release of the at least one drug at therapeutically effective amounts for at least 720 hours.

32. A drug-eluting contact lens as in claim 27 , wherein the at least one drug is released at a rate of at least 0.1 micrograms per hour.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: HOARE, TODD R.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 024524/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: KOHANE, DANIEL S.
To: CHILDREN'S MEDICAL CENTER CORPORATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 024524/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2010
From: CIOLINO, JOSEPH B.
To: MASSACHUSETTS EYE AND EAR INFIRMARY
Reel/Frame 024525/0117 →
Continuity (2)
Provisional Application 61121806 · Dec 11, 2008
Related Publication 20100239637A1 · Sep 23, 2010